Dyadic Expands Animal-Free Dairy Protein Pipeline with European Partnership

Dyadic International, a US-based biotech company, has expanded its animal-free dairy protein pipeline with a new development and commercial license partnership in Europe. This move reflects the company's commercialisation strategy of combining strategic development collaborations with commercial partnerships. The agreement with the European biotech company will provide Dyadic with development and commercial payments, licensing-related revenues, and other potential payouts tied to successful commercialisation. This will create multiple pathways for future profit generation. Dyadic's president and COO, Joe Hazelton, stated that the agreement represents "another important step in expanding Dyadic's commercial food and nutrition pipeline." Dyadic's precision fermentation platform, called Dapibus, solves cost, scale, and regulatory challenges associated with developing recombinant proteins. The platform helps lower the per-kg costs of precision-fermented proteins with high yields, enables consistent production from lab to industrial scale, and achieves native-like taste, texture, and nutrition through proper folding and bioactivity. The company's technology provides a more stable, industrial-level supply of proteins, streamlines the transition from R&D to food-grade with platforms designed for global regulatory compliance, and lowers the associated environmental impact and resource use. Dyadic has already commercialised a range of proteins, including human and bovine alpha-lactalbumin, human lactoferrin, bovine transferrin, and bovine fibroblast growth factor. The new partnership will focus on developing proteins with improved functionality, texture, and nutrition for various food and nutrition applications. The programme will advance through strain optimisation, process development, and commercial scale-up activities. Dyadic's expanding commercial pipeline, strategic partnerships, and proprietary microbial expression platforms open up multiple pathways for revenue creation, from development agreements, strategic collaborations, and licensing, to commercial products and manufacturing opportunities. Dyadic's precision fermentation platform, Dapibus, enables the rapid development and efficient manufacture of new food proteins using established microbial fermentation infrastructure. The company's commercialisation model creates opportunities for development revenue, licensing, commercial participation, and future product sales. Hazelton stated that Dapibus enables Dyadic to "rapidly develop and efficiently manufacture new food proteins using established microbial fermentation infrastructure, while our commercialisation model creates opportunities for development revenue, licensing, commercial participation and future product sales." The new agreement is another example of Dyadic's strategy of leveraging its proprietary microbial expression platforms to develop recombinant protein solutions across multiple markets. Hazelton noted that each new programme further strengthens the Dapibus platform as a repeatable engine for commercial growth.